Page 1

Dexcom® Dexcom Reports Third Quarter 2021 Financial Results October 28 , 2021 SAN DIEGO -- ( BUSINESS WIRE ) -- Oct . 28 , 2021-- DexCom , Inc. ( Nasdaq : DXCM ) today reported its financial results as of and for the quarter ended September 30 , 2021 . Third Quarter 2021 Financial Highlights : • Revenue grew 30 % versus the same quarter of the prior year to $ 650.2 million on a reported basis and 28 % on an organic¹ basis . • U.S. revenue growth of 23 % and international revenue growth of 57 % on a reported basis . International growth was 46 % on an organic¹ basis . • GAAP operating income of $ 118.3 million or 18.2 % of revenue , a decrease of 60 basis points compared to the third quarter of 2020. Non - GAAP operating income * of $ 123.8 million or 19.0 % of revenue , in line with the same quarter of the prior year . Strategic Highlights : • Received FDA clearance for two key software solutions that enhance Dexcom's connected ecosystem : o The Dexcom real - time API makes it possible for third - party developers to integrate real - time CGM data into their digital health apps and devices , ultimately offering Dexcom users a greater variety of options in where and how they engage with their glucose data.² o The Dexcom app - in - app module directly integrates with third party healthcare apps , making managing diabetes easier for Type 2 Non - intensive insulin therapy ( NIIT ) users by enabling a convenient , single - app experience . • Completed the acquisition of our distributor in Australia and New Zealand , advancing Dexcom's strategy to transition certain international markets from distributors to direct sales . • Introduced a new product with the launch of Dexcom ONE , a key addition to our portfolio as we seek to broaden access to healthcare for people with diabetes globally . " In the third quarter Dexcom continued to progress toward our goal of broadening access and advancing our leadership position in CGM - driven connected solutions and customer choice , " said Kevin Sayer , Dexcom's chairman , president and CEO . " We are pleased to once again be in a position to raise our full - year revenue and margin guidance as we drive toward a strong conclusion of 2021 and the upcoming launch of our Dexcom G7 system . " 2 1 Excludes non - CGM revenue acquired in conjunction with Dexcom's acquisition of its distributor in Australia and New Zealand . https://www.dexcom.com/webapi 2021 Annual Guidance Based on the strong third quarter results , Dexcom is increasing its guidance for fiscal year 2021 revenue , Non - GAAP gross profit margin , Non - GAAP operating margin , and Adjusted EBITDA margin to the following levels : • Revenue of approximately $ 2.425 - 2.450 billion ( 26-27 % growth ; Growth includes approximately 1 % from non - CGM acquired revenue in conjunction with Dexcom's acquisition of its distributor in Australia and New Zealand ) • Non - GAAP Gross Profit Margin of approximately 68 % • Non - GAAP Operating Margin of approximately 16 % • Adjusted EBITDA Margin of approximately 25 % Third Quarter 2021 Financial Results Revenue : In the third quarter of 2021 , worldwide revenue grew 30 % to $ 650.2 million , up from $ 500.9 million in the third quarter of 2020. Volume growth in conjunction with strong new customer additions continues to be the primary driver of revenue growth as awareness of real - time CGM increases . Gross Profit : GAAP gross profit totaled $ 446.9 million or 68.7 % of revenue for the third quarter of 2021 , compared to $ 340.4 million or 68.0 % of revenue in the third quarter of 2020 .